In humans, neurodegenerative diseases such as Alzheimer’s disease lead to a depletion of NRGN expression in the brain and an elevation of NRGN levels in the cerebrospinal fluid, changes that are associated with diminished cognitive performance [45,46,47]. This evidence concerns the gene NRGN and Alzheimer disease.